Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2b Clinical Trial Using Multiple Interventions With Distinct Anti-Reservoir Activities In People On Antiretroviral Treatment

NCT07903441 is registered in ClinicalTrials.gov with Federal University of São Paulo as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07903441 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2b Clinical Trial Using Multiple Interventions With Distinct Anti-Reservoir Activities In People On Antiretroviral Treatment
Lead sponsor
Federal University of São Paulo
Phase
Phase 2
Overall status
Recruiting
Start date
August 1, 2026
Completion date
December 31, 2027
Enrollment
70 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hiv - human immunodeficiency virus

Arms

As registered; 2 arms.

  • Control No intervention
  • Multiple therapeutic interventions ExperimentalMultiple therapeutic interventions

Primary endpoints

Registered primary outcome measures; 6 primary.

  • Evolution of viral load of HIV RNA over the time frame of the study by ultrasensitive RT-qPCR baseline, weeks 12, 24, 36 and 48 and every 3 weeks after the antiretroviral ATI up to 36 months after antiretroviral ATI
  • Evolution of cell-associated HIV RNA in PBMCs by qPCR. over the study time frame baseline, weeks 12, 24, 36 and 48 and every 3 weeks after the antiretroviral ATI up to 36 months after antiretroviral ATI
  • Evolution of total DNA and episomal HIV DNA in lymphoid tissue (rectal biopsy) baseline, week 48, after resurgence of viremia in the analytical interruption of antiretrovirals, or after 24 and 96 weeks after analytical interruption of antiretrovirals.

    Quantification by in-house virological assay

  • Evolution of percentages of CD38 and HLA DR in CD4 + and CD8 + T lymphocytes baseline, weeks 12, 24, 36 and 48 and every 3 weeks after the antiretroviral ATI up to 36 months after antiretroviral ATI

    Measurement by flow cytometry of cell activation of CD4+ and CD8+ T lymphocytes as a means of assessing immune and inflammatory responses

  • Evolution of the HIV RNA sequence of the V3 region of gp 120, protease, reverse transcriptase and integrase regions of the pol gene, and of the gag gene baseline, week 24, week 48, after resurgence of viremia after ATI and before reintroduction of ART

    NGS sequencing of the V3 region of gp120, the protease, reverse transcriptase, and integrase regions of the pol gene, and of the gag gene of HIV RNA

+1 more primary endpoint

Lead sponsor's other trials

Federal University of São Paulo, most recent start first.

Similar trials

Same condition (Acquired Immunodeficiency Syndrome) and phase, most recent start first.